Intra cellular Therapies Inc
Officers & Directors
1. Sharon Mates, Ph.D. (Chairman and CEO): Dr. Mates has over 30 years of experience in the pharmaceutical industry and has held senior executive positions at several companies focused on developing treatments for central nervous system disorders. 2. Lawrence J. Hineline, J.D. (Chief Legal Officer and General Counsel): Mr. Hineline has over 20 years of legal experience in the life sciences industry and has been with Intra-Cellular Therapies since 2016. 3. Michael Halstead (Chief Financial Officer): Mr. Halstead has over 20 years of experience in finance and accounting, including executive roles at several publicly traded companies in the biotech industry. Directors: 1. Richard F. Pops (Lead Independent Director): Mr. Pops served as the Chairman and CEO of Alkermes plc, a global biopharmaceutical company, from 1991 to 2021. 2. Robert E. Hoffman: Mr. Hoffman has over 35 years of experience in the pharmaceutical and biotech industries and has held senior executive positions at companies such as Wyeth and Pfizer. 3. Christopher J. Twomey: Mr. Twomey has over 40 years of experience in the pharmaceutical and biotech industries and has served on the board of several publicly traded companies.,
Intra cellular Therapies Inc currently has 202 employees.
News about Intra cellular Therapies Inc Key Personnel |
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a renowned biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system (CNS) disorders, has recently announced the appointment of Sanjeev Narula as their Executive Vice President and Chief Financial Officer. With this strategic move, ITCI aims to reinforce its leadership team and drive continued growth in the dynamic pharmaceutical industry.
New CFO to Drive Financial Strategy:
Sanjeev Narula, an esteemed financial executive, will assume the role of CFO at Intra-Cellular Therapies on August 12, 2024. Mr. Narula brings with him a wealth of experience and expertise in financial manage...
|
Intra-Cellular Therapies, a renowned biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system (CNS) disorders, has made significant changes in its leadership team. The promotion of Michael Halstead, J.D. to the position of President marks a strategic move to leverage his expertise in driving various functional areas within the organization. This article explores the implications of this appointment and the potential for enhanced growth and innovation within Intra-Cellular Therapies.
Enhanced Leadership to Drive Multi-Faceted Functions:
As part of the restructuring, Michael Halstead, who currently serves as Executive Vice Pres...
|
|
